<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5783">
  <stage>Registered</stage>
  <submitdate>11/10/2013</submitdate>
  <approvaldate>11/10/2013</approvaldate>
  <nctid>NCT01963208</nctid>
  <trial_identification>
    <studytitle>Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension</studytitle>
    <scientifictitle>A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1042-0603</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Drug Resistant Partial Onset Seizure</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ganaxolone
Treatment: drugs - Placebo

Experimental: ganaxolone - active

Placebo Comparator: Placebo - placebo, non-active


Treatment: drugs: ganaxolone
200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day

Treatment: drugs: Placebo
placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage change in seizure frequency per 28 days in the double blind period relative to baseline</outcome>
      <timepoint>14 wks (cohort 2)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in seizure frequency per 28 days</outcome>
      <timepoint>9 wks (Cohort 1), 14 wks (Cohort 2) and 52 weeks (both)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of responders experiencing a =50% reduction from baseline to the end of the period, in total partial seizure frequency per 28 days</outcome>
      <timepoint>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of seizure free subjects</outcome>
      <timepoint>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impression of change</outcome>
      <timepoint>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient Global Impression of change</outcome>
      <timepoint>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the number of seizure-free days</outcome>
      <timepoint>9 wks (cohort 1), 14 wks (cohort 2) and 52 weeks (both</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Able to give informed consent in writing, or have a legally authorized representative
             able to do so

          -  Willing to enter and participate for the full term of the double blind phase and
             willing to enter into the open-label phase

          -  Male or female outpatients &gt; 18 years of age

          -  Have a confident diagnosis of drug-resistant epilepsy with partial-onset seizures
             (POS), with or without secondary generalization, for =2 years. Have residual POS
             despite having been treated in the past with at least 2 approved anti-epilepsy drugs
             (AEDs) either alone or in combination

          -  Based on history, subjects would be anticipated to have at least 3 POS during each
             4-week Baseline period and unlikely to have 21 or more consecutive POS-free days

          -  Currently being treated and maintained with a stable regimen of 1, 2, or 3 AEDs

          -  Able and willing to maintain daily seizure calendar

          -  Able and willing to take drug with food twice daily

          -  Sexually active women of childbearing potential must use acceptable birth control and
             have a negative pregnancy test at all visits</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have had previous exposure to ganaxolone

          -  Known sensitivity or allergy to any component in the study drug, progesterone, or
             other related steroid compounds

          -  Exposure to any investigational drug or device &lt; 30 days prior to screening, or plans
             to take another investigational drug at any time during the study

          -  Time of onset of epilepsy treatment &lt; 2 years prior to enrollment

          -  Have generalized epilepsy, such as Lennox-Gastaut syndrome, juvenile myoclonic
             epilepsy, absence epilepsy, or non-epileptic seizures within the last 12- month period
             prior to study entry

          -  Have less than 3 POS seizures in a 28-day period or more than 21 consecutive
             seizure-free days during the Baseline period

          -  Have only simple partial seizures without any observable motor component

          -  Have innumerable seizures or status epilepticus within the last 12-months prior to
             screening

          -  Have more than 100 POS per 4-week Baseline period

          -  Have seizures secondary to illicit drug or alcohol use, infection, neoplasm,
             demyelinating disease, degenerative neurological disease, or central nervous system
             (CNS) disease deemed progressive, metabolic illness, or progressive degenerative
             disease

          -  Current use of vigabatrin is not permitted. If prior use of vigabatrin, must have
             documented stable visual fields

          -  Current use of ezogabine is not permitted. If prior use, must have been off the
             medication for at least 3 months prior to screening and have had documented normal
             fundoscopic exam by ophthalmologist

          -  Are planning surgery, or to be evaluated for surgery, during the double blind phase to
             control seizures including VNS implantation

          -  Are suffering from acute or progressive neurological disease, moderate or severe
             psychiatric disease, or severe mental abnormalities that are likely to require changes
             in drug therapy during the double blind portion of the study or interfere with the
             objectives of the study or the ability to adhere to the protocol requirements

          -  Have a history of an actual suicide attempt in the last 5 years or more than 1
             lifetime suicide attempt

          -  Have a positive urine drug screen at Screening or meet criteria for current or
             historical Substance Use Disorder (DSM-V criteria) within the past 5 years.

          -  Have any medical condition that, in the investigator's judgment, is considered to be
             clinically significant and could potentially affect subject safety or study outcome,
             including but not limited to: clinically significant cardiac, renal, pulmonary,
             gastrointestinal, hematologic or hepatic conditions; or a condition that affects the
             absorption, distribution, metabolism or excretion of drugs

          -  Have elevated ALT (SGPT) or AST (SGOT) greater than 3 times upper limits of normal, or
             total bilirubin greater than 1.5 time ULN

          -  Have a history of malignancy within the past 2 years, with the exception of basal cell
             carcinoma

          -  Are currently following or planning to follow a ketogenic diet

          -  Use of dietary supplements or herbal preparations are not permitted if subject has
             been using them consistently for less than 6 months prior to screening, or does not
             plan on remaining on stable doses for the duration of the double blind phase. Use of
             St. John's Wort is not permitted

          -  Females who are pregnant, currently breastfeeding or planning to become pregnant
             during the duration of the study

          -  A history of chronic noncompliance with drug regimens

          -  Inability to withhold grapefruit and grapefruit juice from diet during the entire
             clinical trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>405</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>The Prince of Wales Hospital - Randwick</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Flinders Medical Center - Bedford Park</hospital>
    <hospital>St. Vincent's Hospital - Fitzroy</hospital>
    <hospital>The Florey Institute of Neuroscience and Mental Health - Heidelberg</hospital>
    <hospital>The Royal Melbourne Hospital - Parkville</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Blagoevgrad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Ruse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bernau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dussseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Jaworowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhniy Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Marinus Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone -
      on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic
      medications (AEDs).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01963208</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Albena Patroneva, M.D.</name>
      <address>Marinus Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>